Phio Pharma Q3 net loss $1.5M, cash $5.4M; PH-762 shows complete response in one patient

Phio Pharmaceuticals Corp.

2024-Q3 EPS reported -$8.23

Net loss narrowed to $1.5M for Q3 2024 vs $2.8M in Q3 2023; R&D expenses fell 64% to $0.6M.
Cash at Sept 30, 2024 was $5.4M, down from $8.5M at Dec 31, 2023.
Phase 1b of PH-762: second cohort enrolled; one complete response (100% tumor clearance) and one partial response (90%) in cutaneous squamous cell carcinoma.
Warrant inducement exercise in July 2024 raised net proceeds of ~$2.6M.
Third cohort screening opens Dec 10, 2024; sixth clinical site added in San Diego.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.